NCT03626545

Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy

The study was early terminated due to the lack of efficacy of study treatment observed in the analysis of the primary endpoint of the randomized part